DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a report released on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Up 3.0 %

Shares of DRRX stock opened at $0.85 on Tuesday. The stock’s 50-day moving average price is $0.94 and its 200-day moving average price is $1.24. DURECT has a 12-month low of $0.62 and a 12-month high of $1.88. The stock has a market capitalization of $26.39 million, a price-to-earnings ratio of -1.39 and a beta of 0.94.

Institutional Trading of DURECT

A hedge fund recently raised its stake in DURECT stock. Geode Capital Management LLC increased its stake in DURECT Co. (NASDAQ:DRRX) by 4.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,658 shares during the period. Geode Capital Management LLC owned approximately 1.03% of DURECT worth $429,000 as of its most recent SEC filing. 28.03% of the stock is currently owned by institutional investors and hedge funds.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.